Home

Inadequate response

Read time: 3 min

Innovation and tailored treatments drive improved outcomes in depression

We are a step closer to the early detection of antidepressant treatment failure, a paradigm shift...

Parkinson's Disease

Read time: 5 min

Congress highlights

Gait freezing - defrosted

The assessment and therapeutic options for complex gait disorders has never been so promising....

Read time: 3 min

Congress highlights

Urgent need to optimize treatment in major depression

Residual symptoms reduce the likelihood of return to pre-depression functioning and increase the...

Read time: 3 min

Congress highlights

When to change first-line treatment: Debating an everyday dilemma

If there is partial response after two to four weeks, persist with current therapy. If not, there...

Read time: 4 min

Congress highlights

Mechanisms underlying clinical manifestations of treatment resistance in schizophrenia

Antipsychotics are not effective in 30% of patients with schizophrenia. These patients have...

Parkinson's Disease

Read time: 4 min

Congress highlights

Non-motor symptoms – influencing ‘ON’ and ‘OFF’ in Parkinson’s disease

A broad spectrum of non-motor symptoms is highly prevalent in Parkinson’s disease (PD) which...

Depression, Schizophrenia

Read time: 4 min

Congress highlights

Towards new treatment options for MDD and schizophrenia: a role for D2 receptor partial agonists

Major depressive disorder (MDD) and schizophrenia share in common the side effect burden associated...

Read time: 3 min

Treatment-resistant schizophrenia – results of a survey on its clinical impact and therapeutic strategies

The results of an online survey completed by 204 US psychiatrists on the clinical impact of...

Read time: 3 min

Treatment-resistant schizophrenia through the lens of observational databases

Longitudinal medical data of patients in healthcare databases may provide a better understanding of...

Read time: 3 min

Brain circuits in depression and response to pharmacotherapy

The symptoms of major depressive disorder (MDD) vary from patient to patient. The primary treatment...

Alzheimer's Disease

Read time: 3 min

How beneficial is cholinesterase inhibition and for whom?

New evidence suggests that cholinesterase inhibition in prodromal Alzheimer’s disease (AD)...

Read time: 3 min

Steps towards more effective and better tolerated treatment options for schizophrenia

New more effective and better tolerated treatments for schizophrenia are needed to improve patient...

Country selection

We are registering that you are located in Brazil - if that's correct then please continue to Progress in Mind Brazil

Not located in Brazil?
Go to a different regional HUB

Continue to Progress in Mind Continue to Progress in Mind Brazil Continue to Progress in Mind Spain Continue to Progress in Mind Italy Continue to Progress in Mind

You are leaving Progress in Mind

Continue to

Cancel

Hello
Please confirm your email

We have just sent you an email, with a confirmation link.
Before you can gain full access - you need to confirm your email.

The information on this site is exclusively intented for health care professionals.

All the information included in the Website is related to products of the local market and, therefore, directed to health professionals legally authorized to prescribe or dispense medications with professional practice. The technical information of the drugs is provided merely informative, being the responsibility of the professionals authorized to prescribe drugs and decide, in each concrete case, the most appropriate treatment to the needs of the patient.

Accept

Decline

Congress

Register for access to Progress in Mind in your country